The Role of Liquid Biopsy in Early Cancer Detection: A Market Overview

The global liquid biopsy market is set to experience extraordinary growth in the coming decade, with revenue estimated at USD 1,538.3 million in 2023. According to leading healthcare experts, this dynamic market is forecasted to expand at a remarkable Compound Annual Growth Rate (CAGR) of 21.7% through 2033, reaching an impressive valuation of USD 10,938.6 million by the end of the forecast period.

Liquid biopsy is rapidly gaining traction as a transformative tool in the field of diagnostics and personalized medicine. This non-invasive technique offers a more accessible and efficient alternative to traditional tissue biopsies, enabling the detection and monitoring of various cancers and other diseases with unprecedented accuracy.

Examine an Enlightening – Report

Liquid biopsies have become more common in recent years due to the desire for more personalized treatment options. Since liquid biopsy is widely available and reasonably priced in many labs, particularly in developing countries, its use is growing in popularity. For instance, several labs offer liquid biopsy tests.

“Key players are bringing cost reductions in liquid biopsy tests and partnering with local product distributors to strengthen their network base in target markets. Currently, a trend toward emerging economies has been spotted, as cancer cases are particularly on the rise, and a large population base provides significant opportunities in these markets,” says an FMI analyst.

Key Takeaways from the Liquid Biopsy Market Report

The North America liquid biopsy market is expected to account for a leading share of 50.84%. The United States is predicted to account for 43.8%, enjoying a dominant share in the global and regional markets.
The Europe market is anticipated to acquire a market share of 19.6% in 2023. Germany holds a prominent share in the region. In 2023, the country is predicted to amass a total of 6.6% share in the global market.
In Europe, the United Kingdom is predicted to expand at a robust CAGR of 26.4% through 2033.
In Asia Pacific, China and India display a remarkable percentage of growth, i.e., 29.7% and 24.4%, respectively, through 2033.
CTC (Circulating Tumor Cells) is projected to obtain a significant market share of 56.9% by biomarker type in 2023.
By sample type, blood sample type holds prominence in the liquid biopsy market.

Key Developments by Liquid Biopsy Market Players

QIAGEN N.V. (the Netherlands), in May 2022, introduced a therascreen EGFR Plus RGQ PCR Kit, which is a new in vitro diagnostic test for the analysis of sensitive EGFR mutation.
Guardant Health, Inc., in June 2021, introduced Guardant360 Response test that finds variations in circulating tumor DNA (ctDNA) levels.
Hoffmann-La Roche Ltd. (Switzerland), in October 2020, gained United States FDA approval for the extended claims for cobas EGFR Mutation Test v2 to be deployed as a companion diagnostic for an extensive range of therapies to manage non-small cell lung cancer (NSCLC).
Biocept, Inc., in March 2020, agreed with a California-based Independent Physician Association (IPA) to offer its Target Selector liquid assay services to patients and physicians in the network.

Key Companies Profiled: